75/100 · Elevated
Manufactured by Mylan Institutional LLC
Calcitonin Salmon Adverse Events: High Serious Reaction Rate
7,597 FDA adverse event reports analyzed
Last updated: 2026-05-12
CALCITONIN SALMON is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Mylan Institutional LLC. Based on analysis of 7,597 FDA adverse event reports, CALCITONIN SALMON has a safety score of 75 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for CALCITONIN SALMON include NAUSEA, DRUG INEFFECTIVE, FALL, PAIN, ARTHRALGIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CALCITONIN SALMON.
Calcitonin Salmon has a safety concern score of 75 out of 100, placing it in the elevated concern category based on analysis of FDA adverse event data. The FDA has received approximately 7,597 adverse event reports for this medication, which is primarily manufactured by Mylan Institutional Llc.
The most commonly reported adverse events include Nausea, Drug Ineffective, Fall. Of classified reports, 71.2% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Nausea and fall are the most common adverse events, with serious reactions comprising 71.2% of all reports.
Pain and dizziness are also frequently reported, indicating potential musculoskeletal and neurological side effects. The wide range of reactions suggests a diverse safety profile, with some serious conditions like pneumonia and myocardial infarction reported.
Patients taking Calcitonin Salmon should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Calcitonin Salmon may interact with other medications affecting bone health or causing dizziness, and should be used with caution in patients with pre-existing conditions. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Calcitonin Salmon received a safety concern score of 75/100 (elevated concern). This is based on a 71.2% serious event ratio across 3,070 classified reports. The score accounts for 7,597 total adverse event reports and 100 distinct reaction types. This elevated score indicates a notable proportion of serious adverse events and warrants careful monitoring.
Adverse event reports by sex: Female: 2,494, Male: 426, Unknown: 6. The most frequently reported age groups are age 74 (70 reports), age 70 (68 reports), age 75 (68 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 3,070 classified reports for CALCITONIN SALMON:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Calcitonin Salmon may interact with other medications affecting bone health or causing dizziness, and should be used with caution in patients with pre-existing conditions.
If you are taking Calcitonin Salmon, here are important things to know. The most commonly reported side effects include nausea, drug ineffective, fall, pain, arthralgia. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Patients should report any unusual symptoms to their healthcare provider immediately. Follow prescribed dosing instructions carefully to minimize the risk of adverse events. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA continues to monitor the safety of Calcitonin Salmon, and updates will be provided as necessary based on ongoing reviews.
The FDA has received approximately 7,597 adverse event reports associated with Calcitonin Salmon. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Calcitonin Salmon include Nausea, Drug Ineffective, Fall, Pain, Arthralgia. By volume, the top reported reactions are: Nausea (250 reports), Drug Ineffective (245 reports), Fall (216 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Calcitonin Salmon.
Out of 3,070 classified reports, 2,186 (71.2%) were classified as serious and 884 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Calcitonin Salmon break down by patient sex as follows: Female: 2,494, Male: 426, Unknown: 6. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Calcitonin Salmon adverse events are: age 74: 70 reports, age 70: 68 reports, age 75: 68 reports, age 67: 67 reports, age 71: 65 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Calcitonin Salmon adverse event reports is Mylan Institutional Llc. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Calcitonin Salmon include: Dizziness, Back Pain, Headache, Dyspnoea, Asthenia. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Calcitonin Salmon to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Calcitonin Salmon has a safety concern score of 75 out of 100 (elevated concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Nausea and fall are the most common adverse events, with serious reactions comprising 71.2% of all reports.
Key safety signals identified in Calcitonin Salmon's adverse event data include: Falls and fractures are notable, suggesting potential musculoskeletal risks.. Serious reactions like pneumonia, myocardial infarction, and death are concerning.. Pain and dizziness are frequently reported, indicating possible side effects on the musculoskeletal and nervous systems.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Calcitonin Salmon may interact with other medications affecting bone health or causing dizziness, and should be used with caution in patients with pre-existing conditions. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Calcitonin Salmon.
Patients should report any unusual symptoms to their healthcare provider immediately. Follow prescribed dosing instructions carefully to minimize the risk of adverse events.
Calcitonin Salmon has 7,597 adverse event reports on file with the FDA. Pain and dizziness are also frequently reported, indicating potential musculoskeletal and neurological side effects. The volume of reports for Calcitonin Salmon reflects both the drug's usage level and the vigilance of the reporting community.
The FDA continues to monitor the safety of Calcitonin Salmon, and updates will be provided as necessary based on ongoing reviews. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Mylan Institutional LLC and compare their safety profiles:
The following drugs share commonly reported adverse reactions with CALCITONIN SALMON:
Drugs related to CALCITONIN SALMON based on therapeutic use, drug class, or shared indications: